文献速递慢性肾脏病遗传性与小管间质肾病

肾小管生物标志物在肾脏疾病中的应用前景综述

The Promise of Tubule Biomarkers in Kidney Disease: A Review.
PubMed 文献 · Am J Kidney Dis · 2021-05-27

该综述指出,血清肌酐作为肾脏疾病检测与监测的主要指标已沿用70余年,而肾小管间质损伤和纤维化在活检研究中高度预示后续肾衰竭,但临床医生在无活检时无法察觉此病理改变。近期发现的反映肾小管疾病不同方面的生物标志物可提供超越eGFR和白蛋白尿的CKD进展及不良临床终点风险信息。综述描述了该领域的独特贡献,讨论了将这些标志物带入临床实践的挑战与要求,倡导超越肾小球聚焦的肾脏健康评估。

要点

  • 肾小管生物标志物可提供超越eGFR和白蛋白尿的CKD进展风险信息
  • 标志物分为肾小管细胞损伤类和肾小管细胞功能障碍类
  • 肾小管生物标志物为监测CKD治疗反应提供新机会

核心结论

  • 肾小管生物标志物可提供超越eGFR和白蛋白尿的CKD进展及不良临床终点风险信息,为监测治疗反应提供新机会。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 肾小管间质损伤和纤维化在活检研究中高度预示后续肾衰竭,但无活检时临床不可见。
  • 肾小管生物标志物可反映肾小管疾病的不同方面,提供超越eGFR和白蛋白尿的风险信息。
  • 标志物可大致分为标记肾小管细胞损伤(如KIM-1、MCP-1)和标记肾小管细胞功能障碍(如α1-微球蛋白、尿调节素)两类。

临床怎么用

  • 倡导更广泛的肾脏健康评估,超越对肾小球的关注。
  • 肾小管生物标志物可用于监测CKD患者对治疗的反应。
  • 此类工具可提高诊断准确性并更早评估CKD患者的治疗疗效或损害。

局限性

  • 将肾小管标志物带入临床实践仍面临挑战和要求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For over 70 years, serum creatinine has remained the primary index for detection and monitoring of kidney disease. Tubulointerstitial damage and fibrosis are highly prognostic for subsequent kidney failure in biopsy studies, yet this pathology is invisible to the clinician in the absence of a biopsy. Recent discovery of biomarkers that reflect distinct aspects of kidney tubule disease have led to investigations of whether these markers can provide additional information on risk of chronic kidney disease (CKD) progression and associated adverse clinical end points, above and beyond estimated glomerular filtration rate and albuminuria. These biomarkers can be loosely grouped into those that mark tubule cell injury (eg, kidney injury molecule 1, monocyte chemoattractant protein 1) and those that mark tubule cell dysfunction (eg, α1-microglobulin, uromodulin). These kidney tubule biomarkers provide new opportunities to monitor response to therapeutics used to treat CKD patients. In this review, we describe results from some unique contributions in this area and discuss the current challenges and requirements in the field to bring these markers to clinical practice. We advocate for a broader assessment of kidney health that moves beyond a focus on the glomerulus, and we highlight how such tools can improve diagnostic accuracy and earlier assessment of therapeutic efficacy or harm in CKD patients.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ix JH, Shlipak MG. The Promise of Tubule Biomarkers in Kidney Disease: A Review. Am J Kidney Dis. 2021. PMID: 34051308. doi:10.1053/j.ajkd.2021.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。